To the Editor We read with interest the article by Kurian et al,1 who used a binary outcome superiority crossover randomized clinical trial to investigate the efficacy of topical timolol for treatment of acute migraine attacks, and the adjoining commentary.2 We wish to bring to the authors’ attention a few points of interest regarding their study.
Brar AS, Brar MK. Additional Considerations Regarding Timolol Eyedrops for Acute Treatment of Migraine. JAMA Ophthalmol. 2021;139(8):920. doi:10.1001/jamaophthalmol.2021.1783
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.